Novo Nordisk A/S: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Novo Nordisk in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

• Benchmark Novo Nordisk's performance against key rivals in the prescription pharmaceutical sector
• Assess the company's highly focused strategy, centred on the use of therapeutic proteins and internally sourced R&D
• Analyze how Novo Nordisk's dominance in the diabetes market will elevate the company to the Big Pharma peer set by 2010

• About Datamonitor Healthcare
  • about the PharmaVitae team
• Chapter 1 about This Profile
  • PharmaVitae Explorer database
• Chapter Structure
  • Data sourcing
• Chapter 2 Executive Summary
  • Key findings
  • Prescription pharmaceutical sales and growth rate performance, 2002??